Company

BeiGene Ltd

Headquarters: Beijing, China

Employees: 8,000

CEO: Mr. John V. Oyler

Market Cap

HK$136.19 Billion

HKD as of Jan. 1, 2024

US$17.44 Billion

history Market Cap History

BeiGene Ltd market capitalization over time

Evolution of BeiGene Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of BeiGene Ltd

Detailed Description

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.

🐷

"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Stocks & Indices

BeiGene Ltd has the following listings and related stock indices.


Stock: HKEX: 6160 wb_incandescent

Stock: NASDAQ: BGNE wb_incandescent

Stock: FSX: 49B wb_incandescent

Stock: Bovespa: B1GN34 wb_incandescent

Stock: FSX: 49BA wb_incandescent

Details

Headquarters:

No.30 Science Park Road

Zhong-Guan-Cun Life Science Park Changping District

Beijing, 102206

China

Phone: 86 01 0851 48500